Nebicard (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebicard, is a beta‑adrenergic blocker presented as an oral tablet for oral use. It lowers elevated blood pressure and improves cardiac function in patients with heart failure, offering vasodilatory benefits through nitric‑oxide release and is approved in the European Union for these indications.

GNH USA supplies Nebicard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance. Our distribution network ensures timely delivery to diverse healthcare settings across multiple continents.

Nebivolol is a selective β1‑adrenergic blocker used in cardiovascular disease management.

Hypertension: reduces systolic and diastolic blood pressure to achieve guideline‑recommended targets. Heart failure (reduced ejection fraction): improves left ventricular ejection fraction and lowers risk of hospitalization. Post‑myocardial infarction: assists in blood pressure control to diminish the likelihood of recurrent cardiovascular events.

Nebivolol may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or general tiredness. - Nasal congestion or rhinorrhea. - Bradycardia: heart rate below 60 bpm. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe bradycardia or symptomatic heart block. - Marked hypotension with syncope. - Bronchospasm in patients with reactive airway disease. - Allergic reactions including rash, pruritus, or angioedema. - Hepatic enzyme elevation or liver injury. - Worsening heart failure or pulmonary edema.

Before initiating Nebicard, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Heart rate assessment: watch for bradycardia, especially in patients with conduction disorders. - Respiratory caution: use carefully in asthma or COPD due to possible bronchospasm. - Renal/hepatic function: adjust therapy if significant impairment is present. - Discontinuation: taper gradually to prevent rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebicard can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other beta‑blockers: additive bradycardia and hypotension. - Calcium‑channel blockers (verapamil, diltiazem): increased risk of AV‑block and severe bradycardia. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine): may raise nebivolol plasma concentrations. - Anti‑arrhythmic agents (amiodarone, quinidine): heightened cardiac conduction disturbances.

Moderate Interactions (Monitor Closely):\n- Diuretics: may potentiate hypotensive effect. - ACE inhibitors or ARBs: monitor for excessive blood pressure drop. - NSAIDs: can blunt antihypertensive response. - Clonidine: abrupt withdrawal may cause rebound hypertension. - Insulin or oral hypoglycemics: beta‑blockade may mask hypoglycemia symptoms.